Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 22;20(4):965.
doi: 10.3390/ijms20040965.

Advances in Therapeutic Implications of Inorganic Drug Delivery Nano-Platforms for Cancer

Affiliations
Review

Advances in Therapeutic Implications of Inorganic Drug Delivery Nano-Platforms for Cancer

Safia Naz et al. Int J Mol Sci. .

Abstract

Numerous nanoparticles drug delivery systems for therapeutic implications in cancer treatment are in preclinical development as conventional chemotherapy has several drawbacks. A chemotherapeutic approach requires high doses of chemotherapeutic agents with low bioavailability, non-specific targeting, and above all, development of multiple drug resistance. In recent years, inorganic nano-drug delivery platforms (NDDPs; with a metal core) have emerged as potential chemotherapeutic systems in oncology. One of the major goals of developing inorganic NDDPs is to effectively address the targeted anti-cancer drug(s) delivery related problems by carrying the therapeutic agents to desired tumors sites. In this current review, we delve into summarizing the recent developments in targeted release of anti-cancer drugs loaded in inorganic NDDPs such as mesoporous silica nanoparticles, carbon nanotubes, layered double hydroxides, superparamagnetic iron oxide nanoparticles and calcium phosphate nanoparticles together with highlighting their therapeutic performance at tumor sites.

Keywords: cancer; drug delivery; inorganic agents; nano-carriers; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic diagram depicting various inorganic NDDPs loaded with anti-cancer chemotherapeutic agents employed for cancer treatment. iNPs: inorganic nanoparticles; MWCNTs: multi-walled carbon nanotubes, SWCNTs: single-walled carbon nanotubes.

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA A Cancer J. Clin. 2019;69:7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. Bray F., Jemal A., Grey N., Ferlay J., Forman D. Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol. 2012;13:790–801. doi: 10.1016/S1470-2045(12)70211-5. - DOI - PubMed
    1. Wang S.H., Yu J. Structure-based design for binding peptides in anti-cancer therapy. Biomaterials. 2018;156:1–15. doi: 10.1016/j.biomaterials.2017.11.024. - DOI - PubMed
    1. Luo C., Sun J., Sun B., He Z. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy. Trends Pharmacol. Sci. 2014;35:556–566. doi: 10.1016/j.tips.2014.09.008. - DOI - PubMed
    1. Dissanayake S., Denny W.A., Gamage S., Sarojini V. Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. J. Control. Release. 2017;250:62–76. doi: 10.1016/j.jconrel.2017.02.006. - DOI - PubMed

LinkOut - more resources